Experts debate which patients with stage III dMMR colon cancer will benefit from the two treatment approaches.

The FDA approved an investigational new drug application for ABT-301, clearing the way for a new clinical trial in metastatic ...

Anbogen Therapeutics gains FDA approval for ABT-301, initiating a pivotal trial for metastatic colorectal cancer, targeting ...

HOXB13, a B-class homeobox transcription factor, sits at the hub of developmental gene networks yet has emerged as a ...

The Phase I/II trial will evaluate the safety and early efficacy of ABT-301 in combination with tislelizumab and bevacizumab ...

HOXB13, a B-class homeobox transcription factor, sits at the hub of developmental gene networks yet has emerged as a ...

New research has uncovered a novel mechanism that may help explain why some people with cancer respond remarkably well to ...

Researchers discovered that interleukin-6 (IL-6) in colorectal cancer triggers a STAT3-to-PI3K signaling switch in cancer stem cells (CSCs), enabling potent PD-L1 upregulation and immune evasion.

Chemotherapy and immunotherapy are key cancer treatments. Chemotherapy targets fast-growing cells. Immunotherapy uses the ...

Colorectal cancer is among the most prevalent and lethal malignancies worldwide, with liver metastases occurring in nearly one-third of patients and accounting for a major share of cancer-related ...

Researchers have discovered new pathways that may explain differences in the way people with cancer respond to ...